A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria

Trial Profile

A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Lyophilised Oxalobacter formigenes (Primary)
  • Indications Primary hyperoxaluria
  • Focus Therapeutic Use
  • Sponsors OxThera
  • Most Recent Events

    • 27 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 04 Sep 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top